1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited

TORNTPHARM.NS
Torrent Pharmaceuticals LimitedIN flagNational Stock Exchange of India
4,822.70
INR
+54.40
- -
1.63TMarket Cap
Torrent Pharmaceuticals Limited
TORNTPHARM.NS
(National Stock Exchange of India)

Recent

price

4,822.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
62.48
76.61
90.07
119.14
135.29
192.63
167.59
172.11
220.47
229.87
233.01
248.75
279.62
312.08
334.39
- -
406.46
Revenue per Share
7.98
8.39
12.79
19.62
22.19
51.21
27.58
20.04
12.89
30.28
36.99
22.96
36.79
48.94
56.47
- -
63.93
Basic EPS, GAAP
3.84
9.98
-4.12
5.89
16.77
63.32
15.42
3.04
33.54
29.14
49.35
47.29
53.01
83.72
58.3
- -
- -
Free Cash Flow per Basic Share
1.75
4.06
2.47
7.9
5.9
24.81
6.02
7.82
9.15
21.23
10
20
25.5
30
32
- -
- -
Dividend per Share
28.54
6.18
10.63
23.39
41.71
45.11
47.24
48.41
50.26
58.43
85.42
88.68
102.6
121.49
5
- -
5
Book Value per Share
29.65
34.67
41.36
55.38
21.64
47.59
73.19
-30.7
-10.65
3.19
44.63
63.45
22.78
57.18
88.3
- -
-321.21
Tangible Book Value per Share
338
338
338
338
338
338
338
338
338
338
338
338
338
338
338
- -
338
Basic Weighted Avg Shares
21,147
25,928
30,485
40,323
45,788
65,194
56,722
58,248
74,618
77,800
78,862
84,188
94,637
105,623
113,172
137,530
137,530
Sales/Revenue/Turnover
15.97
17.02
20.55
23.62
18.11
38.82
19.11
16.15
18.34
19.52
23.11
21.02
22.61
24.35
25.85
25.01
25.01
Operating Margin (%)
626
817
827
870
1,907
2,376
3,069
4,086
6,177
6,544
6,573
6,619
7,020
7,953
7,949
11,189
11,190
Depreciation Expense
2,702
2,840
4,328
6,639
7,509
17,332
9,336
6,781
4,363
10,247
12,519
7,772
12,452
16,564
19,112
21,634
21,630
Net Income, GAAP
21.08
20.17
25.22
21.34
20.09
26.04
14.2
27.16
22.32
13.64
17.98
36.6
32.59
29.58
28.49
25.56
25.56
Effective Tax Rate (%)
12.78
10.95
14.2
16.46
16.4
26.59
16.46
11.64
5.85
13.17
15.87
9.23
13.16
15.68
16.89
15.73
15.73
Profit Margin (%)
4,803
6,243
8,502
12,299
13,938
14,027
21,411
602
-1,278
-4,751
6,299
7,499
-1,336
1,862
9,054
10,486
10,486
Working Capital
2,930
3,220
4,545
7,445
21,729
18,501
22,408
41,115
39,129
33,038
29,633
21,600
25,492
16,682
13,376
118,412
118,412
LT Debt
10,240
11,973
14,223
19,028
26,434
34,946
43,506
46,227
47,244
48,232
58,372
59,530
61,981
68,562
75,907
175,848
175,848
Total Equity
19.24
22.18
24.26
29.38
15.86
33.28
14.57
7.62
9.71
12.21
13.96
10.78
13.33
16.02
19.1
11.76
11.76
Return on Invested Capital (%)
22.19
28.42
48.78
46.41
28.88
46.61
27.73
14.74
10.42
18.15
19.76
12.64
18.47
22.44
36.35
17.83
17.83
Return on Capital (%)
30.07
48.34
152.09
115.31
68.17
117.98
59.74
41.9
26.13
55.71
51.43
26.38
38.47
43.68
89.29
1,278.36
1,278.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
15,790
- -
31,843
LT Borrowings
10,450
- -
116,512
LT Finance Leases
1,980
- -
1,901
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
338
- -
338
Market Capitalization
1,219,454
1,303,238
1,427,942

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
61,710
- -
93,919
Cash, Cash Equivalents & STI
10,330
- -
23,552
Accounts Receivable, Net
21,850
- -
30,309
Inventories
24,670
- -
31,382
Total Current Liabilities
44,350
- -
83,433
Payables & Accruals
- -
- -
- -
ST Debt
15,790
- -
31,843
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.52%
31.82%
131.66%
Free Cash Flow
95.79%
10.87%
18.86%
Net Income, GAAP
13.18%
16.78%
13.19%
Sales/Revenue/Turnover
8.29%
11.89%
21.52%
Total Cash Common Dividend
22.12%
34.17%
19.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25,480
26,280
26,910
26,953
105,623
2025
28,150
28,310
27,620
29,090
113,172
2026
31,280
32,460
32,510
41,280
137,530

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.18
11.39
13.1
- -
48.94
2025
13.51
13.37
14.88
14.71
56.47
2026
16.19
17.45
18.77
11.51
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
30
2025
- -
- -
- -
- -
32
2026
- -
- -
- -
- -
- -
Similar Companies
Natco Pharma Limited (NATCOPHARM.NS)
ZIM Laboratories Limited (ZIMLAB.BO)
Better Plant Sciences Inc. (PLNT.CN)
Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ)
Zhejiang AngLiKang Pharmaceutical CO.,LTD. (002940.SZ)
Brooks Laboratories Limited (BROOKS.NS)
Business
Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Limited (TORNTPHARM.NS), the flagship company of Torrent Group founded in 1959 and headquartered in Ahmedabad, India, manufactures and markets a broad portfolio of branded and generic pharmaceutical formulations across key therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infectives, pain management, women's healthcare, vitamins minerals and nutrients, oncology, nephrology, pulmonology, gynecology, and pediatrics; it offers finished dosage forms such as tablets, capsules, semi-solids including creams gels ointments and lotions, alongside active pharmaceutical ingredients and contract manufacturing services. The company pioneered niche marketing in India and maintains leading positions in cardiovascular and central nervous system therapies, with significant presence in over 50 countries encompassing the US, EU including Germany and UK, Brazil, and emerging markets through wholly-owned subsidiaries in 15 countries. In recent developments, Torrent Pharmaceuticals Limited secured Competition Commission of India approval in October 2025 for its acquisition of a controlling 46.4% stake in J.B. Chemicals & Pharmaceuticals Limited from KKR at an equity valuation of approximately INR 25,689 crores, to be followed by an open offer and merger that will enhance its branded generics portfolio in ophthalmology, IVF, nephrology, and anti-parasitics while providing entry into the high-margin contract development and manufacturing organization business; it has also pursued strategic US manufacturing expansions, chronic therapy innovations, and partnerships such as with Novartis for cardiovascular drugs like inclisiran.